FRANCE'S NATURAL & LIFE PLANS ORAL DRUG PLANT NEAR CHENNAI

Article Abstract:

The Natural & Life group of France and the Tamil Nadu Industrial Development Corporation Ltd (Tidco) are putting up an oral drug plant on the Old Mahabalipuram Road, near Chennai. The project is estimated to cost Rs6 crore in the first phase. It will commence production by December 1998 and export up to 25 percent of its production. It will have a capacity to make two million units a year. It plans to launch six aroma therapy oral products in India. The company is likely to buy 70 percent of its raw materials like essential oils from India. Tidco will have 11 percent stake and the French company 74 percent stake in the project. (rk)

Comment:

Puts up oral drug plant on the Old Mahabalipuram Road, near Chennai with Natural and Life

Research & development outlays, Oral Osmotic Drug Delivery Sys, Oral osmotic drug delivery systems, Natural and Life, Tamil Nadu Industrial Development Corporation Ltd.

---

ZYDUS IN JV WITH KOREAN CO

Article Abstract:

The Zydus group has tied up with Korea Green Cross Corporation (KGCC) of Korea. The joint venture will produce and market recombinant hepatitis-B vaccine in India. Zydus will hold a 60 percent stake in venture while the rest will be held by KGCC. Zydus proposes to set up Rs10 crore worth production facility for producing vaccines at its new plant premises. The new company is expected to start production of the hepatitis-B vaccine by March 1999. (ag)

Comment:

Ties up with Zydus to will produce and market recombinant hepatitis-B vaccine in India

New capacity, new plant construction, Vaccines for Human Use, Vaccines, Zydus, Korean Green Cross Corp.

---

INTAS PHARMA IN BIOTECH JV WITH TWO FIRMS

Article Abstract:

Intas Pharmaceuticals Ltd of Ahmedabad has entered into a marketing joint venture with Pablo Cassara of Argentina and Pinal Pharmaceuticals of South America to market a range of biotech products in India. The venture will market oncology products and cancer-related biotech drugs initially. The alliance is expected to be converted into a technology transfer agreement so that Intas can produce the products in India. (khr)

Comment:

Intas Pharmaceuticals Ltd of Ahmedabad has entered into a marketing joint venture with Pablo Cassara of Argentina and Pinal Pharmaceuticals of South America to market a range of biotech products in India.

Anticancer Drugs, South America, Antineoplastic agents, Intas Pharmaceuticals Ltd, Pablo Cassara and Pinal Pharmaceuticals

Similar abstracts:

• Abstracts: BUNDY INDIA INAUGURATES Rs1.8-CR PLANT IN CHENNAI. RCF IN JV TALKS WITH HZL, INDO-GULF FOR DAP PROJECT PILKINGTON'S Rs100-CRORE GLASS PLANT IN TN SHELVED
• Abstracts: OIL AND NATURAL GAS CORPORATION LIMITED GAIL PLANS 2 POWER PLANTS ALONG HBJ GAS PIPELINE
• Abstracts: HOTEL LEELAVENTURE LIMITED ITDC PLANS THREE-STAR HOTEL IN JOINT VENTURE WITH TTDC
• Abstracts: SILVER LINES THE SMUGGLER'S CHEST CHANGE IN ROUTE PUSHES GOLD, SILVER IMPORTS UP 253%. ANTI-DUMPING DUTY ON ACETYLENE BLACK
• Abstracts: IOC GETS KEY SUPPLIER STATUS FROM RIL, ESSAR. DHIRUBHAI IN ASIAWEEK HALL OF FAME. DHIRUBHAI GETS WHARTON AWARD

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.